Condition
Neuroendocrine Prostate Cancer
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results67% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (2)
Trial Status
Completed2
Terminated1
Recruiting1
Not Yet Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07006727Phase 1Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT04702737Phase 1CompletedPrimary
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
NCT07024277Phase 2Not Yet RecruitingPrimary
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
NCT02709889Phase 1Terminated
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
NCT01799278Phase 2Completed
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Showing all 5 trials